Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GMED Stock Forecast 2026-2027
$77.00
Current Price
$10.66B
Market Cap
Buy 10
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to GMED Price Targets
+58.4%
To High Target of $122.00
+43.5%
To Median Target of $110.50
+13.0%
To Low Target of $87.00
GMED Price Momentum
-1.4%
1 Week Change
-2.8%
1 Month Change
+36.7%
1 Year Change
-11.8%
Year-to-Date Change
-24.1%
From 52W High of $101.40
+48.7%
From 52W Low of $51.79
📊 TOP ANALYST CALLS
Did GMED Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Globus Medical is one of their latest high-conviction picks.
Latest GMED Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, GMED has a bullish consensus with a median price target of $110.50 (ranging from $87.00 to $122.00). The overall analyst rating is Strong Buy (8.4/10). Currently trading at $77.00, the median forecast implies a 43.5% upside. This outlook is supported by 10 Buy, 4 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GMED Analyst Ratings
10
Buy
4
Hold
0
Sell
GMED Price Target Range
Low
$87.00
Average
$110.50
High
$122.00
Current: $77.00
Latest GMED Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GMED.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 13, 2026 | RBC Capital | Shagun Singh | Outperform | Maintains | $115.00 |
| Jul 9, 2026 | BMO Capital | Outperform | Initiates | $94.00 | |
| Jul 8, 2026 | Stifel | Tom Stephan | Hold | Maintains | $80.00 |
| Jun 15, 2026 | Piper Sandler | Overweight | Maintains | $N/A | |
| May 8, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| May 8, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| May 8, 2026 | Needham | Buy | Maintains | $N/A | |
| Feb 26, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Feb 25, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Feb 25, 2026 | Needham | Buy | Maintains | $N/A | |
| Jan 30, 2026 | Needham | Buy | Upgrade | $N/A | |
| Jan 9, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Jan 8, 2026 | Piper Sandler | Overweight | Reiterates | $N/A | |
| Dec 17, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Dec 17, 2025 | RBC Capital | Outperform | Maintains | $N/A | |
| Dec 17, 2025 | Freedom Capital Markets | Hold | Initiates | $N/A | |
| Dec 2, 2025 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Nov 18, 2025 | Truist Securities | Buy | Reiterates | $N/A | |
| Nov 10, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Nov 7, 2025 | RBC Capital | Outperform | Maintains | $N/A |
Globus Medical Inc. (GMED) Competitors
The following stocks are similar to Globus Medical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
GMED
Globus Medical
mkt cap
10.60B
Globus Medical Inc. (GMED) Financial Data
Globus Medical Inc. has a market capitalization of $10.66B with a P/E ratio of 17.5x. The company generates $3.10B in trailing twelve-month revenue with a 18.9% profit margin.
Revenue growth is +27.0% quarter-over-quarter, while maintaining an operating margin of +21.3% and return on equity of +13.3%.
Valuation Metrics
Market Cap
$10.66B
Enterprise Value
$10.31B
P/E Ratio
17.5x
PEG Ratio
0.3x
Price/Sales
3.3x
Growth & Margins
Revenue Growth (YoY)
+27.0%
Gross Margin
+69.2%
Operating Margin
+21.3%
Net Margin
+18.9%
EPS Growth
+64.7%
Financial Health
Cash/Price Ratio
+6.0%
Current Ratio
4.6x
Debt/Equity
2.5x
ROE
+13.3%
ROA
+8.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Globus Medical Inc. (GMED) Business Model
About Globus Medical Inc.
What They Do
Develops implantable devices for musculoskeletal conditions.
Business Model
The company generates revenue by designing, manufacturing, and selling a range of medical devices and biologics for spinal, orthopedic, and neurosurgical procedures. It focuses on innovative solutions and provides education and support to healthcare professionals, enhancing the adoption of its products and driving sales.
Additional Information
Founded in 2003 and based in Audubon, Pennsylvania, Globus Medical is recognized for its commitment to solving clinical needs through advanced technologies such as robotics and navigation systems. Their emphasis on education and clinical support positions them as a leader in improving patient outcomes in musculoskeletal care.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
6,000
CEO
Mr. Keith W. Pfeil
Country
United States
IPO Year
2012
Website
www.globusmedical.comGlobus Medical Inc. (GMED) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
GMED Stock Surges 43.6% in a Year: What's Driving the Rally?
Globus Medical's 43.6% one-year rally is fueled by strong growth across both business segments, rising technology adoption and a debt-free balance sheet.
Jul 17, 2026
By Zacks Equity Research
Analyst Blog
Reasons to Retain Alignment Healthcare Stock in Your Portfolio for Now
ALHC's AI and automation are boosting margins and efficiency, but CMS risk model changes and revenue timing cloud near-term earnings visibility.
Jul 16, 2026
By Zacks Equity Research
Analyst Blog
Can ISRG Defend Its Leadership as Global Competition Intensifies?
ISRG is countering rising global robotic surgery competition with tiered platforms, AI features and a broad ecosystem focused on value over price.
Jul 15, 2026
By Indrajit Bandyopadhyay
Analyst Blog
Latest News
Quick Summary
Zacks Style Scores help investors identify top-rated stocks tailored to their investing style, presenting an opportunity for enhanced stock selection.
Why It Matters
Zacks Style Scores provide a straightforward method to identify high-potential stocks, aiding investors in making informed decisions aligned with their strategies.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Globus Medical shows stronger growth and innovation compared to Medtronic, with analysts indicating potential upside, despite its higher valuation.
Why It Matters
Globus Medical's superior growth and innovation, along with analyst optimism, suggest potential for higher returns, making it an attractive option despite its higher valuation compared to Medtronic.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Zacks Style Scores help investors identify top-rated stocks tailored to their investing style, providing a useful tool for stock selection.
Why It Matters
The Zacks Style Scores provide a systematic approach to identify high-potential stocks, aiding investors in making informed decisions and optimizing their portfolios.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Globus Medical (GMED) shares rose significantly with above-average trading volume. Positive earnings estimate revisions may lead to further price increases soon.
Why It Matters
Globus Medical's share surge and increased trading volume signal strong investor interest, while positive earnings estimate revisions suggest potential for continued price growth.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Globus Medical is experiencing inflation, geopolitical, and currency pressures, which are impacting its margin flexibility and hindering international growth.
Why It Matters
Rising costs and currency losses may impact Globus Medical's profitability and growth potential, affecting investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Investors in the Medical - Instruments sector may consider Globus Medical (GMED) or Penumbra (PEN) for potential value opportunities.
Why It Matters
The comparison between Globus Medical and Penumbra highlights potential investment opportunities in the Medical - Instruments sector, influencing stock selection and value assessment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About GMED Stock
What is Globus Medical Inc.'s (GMED) stock forecast for 2027?
Based on our analysis of 5 Wall Street analysts, Globus Medical Inc. (GMED) has a median price target of $110.50. The highest price target is $122.00 and the lowest is $87.00.
Is GMED stock a good investment in 2027?
According to current analyst ratings, GMED has 10 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $77.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GMED stock?
Wall Street analysts predict GMED stock could reach $110.50 in the next 12 months. This represents a 43.5% increase from the current price of $77.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Globus Medical Inc.'s business model?
The company generates revenue by designing, manufacturing, and selling a range of medical devices and biologics for spinal, orthopedic, and neurosurgical procedures. It focuses on innovative solutions and provides education and support to healthcare professionals, enhancing the adoption of its products and driving sales.
What is the highest forecasted price for GMED Globus Medical Inc.?
The highest price target for GMED is $122.00 from at , which represents a 58.4% increase from the current price of $77.00.
What is the lowest forecasted price for GMED Globus Medical Inc.?
The lowest price target for GMED is $87.00 from at , which represents a 13.0% increase from the current price of $77.00.
What is the overall GMED consensus from analysts for Globus Medical Inc.?
The overall analyst consensus for GMED is bullish. Out of 5 Wall Street analysts, 10 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $110.50.
How accurate are GMED stock price projections?
Stock price projections, including those for Globus Medical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 2:28 AM UTC